All AbMole products are for research use only, cannot be used for human consumption.
Inotuzumab MMAE is an anti-CD22 antibody-drug conjugate (ADC).
Human Siglec-2/CD22 HEK293 Cell Line were stained with Inotuzumab-MMAE and negative control protein respectively, washed and then followed by PE and analyzed with FACS, the EC50 is 0.16 μg/mL.
The drug-to-antibody ratio (DAR) of the Inotuzumab-MMAE is 4.0.
| Storage | Store at ≤ -20℃ for 24 months. Avoid repeated freeze-thaw cycles. |
| Related Antibody-Drug Conjugates (ADCs) Products |
|---|
| Ensituximab-MMAE
Ensituximab-MMAE is an antibody-drug conjugate (ADC) targeting a variant of MUC5AC. |
| Ecromeximab-MMAE
Ecromeximab-MMAE is an antibody-drug conjugate (ADC) targeting ganglioside GD3. |
| Ulocuplumab-MMAE
Ulocuplumab-MMAE is an antibody-drug conjugate (ADC). |
| Lorvotuzumab-MMAE
Lorvotuzumab-MMAE is an antibody-drug conjugate (ADC). |
| Anetumab-MMAE
Anetumab-MMAE is an antibody-drug conjugate (ADC). |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
